ArticleScience translational medicine2017
Genetic and epigenetic inactivation of
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Cross-Trait Meta-Analysis Reveals a Genetic Link between Inflammation and Aging in Giant Cell Arteritis.Aging and disease · 2025Pooled it
- Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Mechanisms of mTORC1 and GCN2 amino acid sensing pathways in tumorigenesis and metastatic progression (Review).International journal of molecular medicine · 2026Review
- Developmental stage and cellular context determine oncogenic and molecular outcomes ofBlood neoplasia · 2025Article
- Review
- p53-regulated SESN1 and SESN2 regulate cell proliferation and cell death through control of STAT3.Cell communication and signaling : CCS · 2025Article
- Levels of Sestrin-1 in Rheumatoid Arthritis Patients: Exploring the Association with Atherosclerosis.International journal of general medicine · 2025Article
- Emerging roles for methionine metabolism in immune cell fate and function.Frontiers in immunology · 2025Review
- Follicular lymphoma regulatory T-cell origin and function.Frontiers in immunology · 2024Article
- The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas.Blood advances · 2023Article
- Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma.Nature communications · 2023Article
- Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia.Leukemia · 2023Article
- Modeling the crosstalk between malignant B cells and their microenvironment in B-cell lymphomas: challenges and opportunities.Frontiers in immunology · 2023Review
- Advances in the multi-omics landscape of follicular lymphoma.International journal of biological sciences · 2023Review
- Biology of follicular lymphoma: insights and windows of clinical opportunity.Hematology. American Society of Hematology. Education Program · 2022Article
- Diversity of Circulating NKT Cells in Defense against Carbapenem-Resistant Klebsiella Pneumoniae Infection.Journal of personalized medicine · 2022Article
- Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular Lymphomas.HemaSphere · 2022Article
- Follicular lymphoma-associated mutations in the V-ATPase chaperone VMA21 activate autophagy creating a targetable dependency.Autophagy · 2022Article
- Mechanisms of Polycomb group protein function in cancer.Cell research · 2022Review
- [Clinical characteristics of patients with multiple myeloma harboring 6q deletion].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 4 countries.
Elisa OricchioSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. elisa.oricchio@epfl.ch.ORCID 0000-0002-1690-0447
Natalya KatanayevaSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0002-4240-1254
Maria Christine DonaldsonSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0001-6403-6713
Stephanie SungaleeSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0001-5633-8826
Joyce P PasionCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-5396-9507
Wendy BéguelinDivision of Hematology/Oncology, Weill Cornell Medical College, Cornell University, 1300 York Avenue, New York, NY 10065, USA.
Elena BattistelloSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0002-8684-388X
Viraj R SanghviCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Man JiangCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-1818-7427
Yanwen JiangInstitute for Computational Biomedicine, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA.
Matt TeaterInstitute for Computational Biomedicine, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA.ORCID 0000-0001-9415-1659
Anita ParmigianiDepartment of Human and Molecular Genetics, Goodwin Research Laboratories, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0002-1780-0376
Andrei V BudanovDepartment of Human and Molecular Genetics, Goodwin Research Laboratories, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Fong Chun ChanCentre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada.
Sohrab P ShahDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-6402-523X
Robert KridelCentre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada.ORCID 0000-0003-0287-7124
Ari M MelnickDivision of Hematology/Oncology, Weill Cornell Medical College, Cornell University, 1300 York Avenue, New York, NY 10065, USA.
Giovanni CirielloDepartment of Computational Biology, University of Lausanne, 1005 Lausanne, Switzerland.
Hans-Guido WendelCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-7166-4670
École Polytechnique Fédérale de Lausanne · CHCornell University · USMemorial Sloan Kettering Cancer Center · USBC Cancer Agency · CAVirginia Commonwealth University · USUniversity of Lausanne · CH
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTranslating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ZELENETZ, ANDREW D. · 2016 to 2020
$10.9MThe genomic pathogenesis of Follicular LymphomaR01CA190384 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MALEK, SAMI NIMER, WENDEL, HANS-GUIDO · 2015 to 2019
$2.7MTowards The Chemotherapy-Free Treatment of Follicular LymphomaR01CA183876 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI WENDEL, HANS-GUIDO · 2014 to 2018
$2.5MExploring oncogenic translation programs in cancerR01CA207217 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI WENDEL, HANS-GUIDO · 2016 to 2020
$2.1MTargeting EZH2 in Germinal Center Derived B-Cell LymphomaR01CA187109 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2014 to 2017
$1.8MThe Role of p53-inducible Sesn1 and Sesn2 genes in lung carcinogenesisR01CA172660 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GROSSMAN, STEVEN R. · 2013 to 2017
$1.5MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA172660NCI NIH HHS R01 CA183876NCI NIH HHS R01 CA187109NCI NIH HHS R01 CA190384NCI NIH HHS R01 CA207217Swiss National Science Foundation 159637
Abstract
Follicular lymphoma (FL) is an incurable form of B cell lymphoma. Genomic studies have cataloged common genetic lesions in FL such as translocation t(14;18), frequent losses of chromosome 6q, and mutations in epigenetic regulators such as
Indexed as
Epigenesis, GeneticAnimalsChromosome DeletionChromosomes, Human, Pair 6Enhancer of Zeste Homolog 2 ProteinGene SilencingGenetic TestingGenome, HumanHeat-Shock ProteinsHumansLymphoma, FollicularMechanistic Target of Rapamycin Complex 1MiceMutationProtein BiosynthesisRNA, MessengerEnhancer of Zeste Homolog 2 ProteinHeat-Shock ProteinsMechanistic Target of Rapamycin Complex 1RNA, MessengerSESN1 protein, humanSestrins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.